Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Calcium carbonate, Colecalciferol; cholecalciferol may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
FOR
Calcichew-D3 Chewable Tablets are orange flavoured chewable tablets containing calcium and vitamin D3 which are both important substances in bone formation. Both are found in the diet and vitamin D is also produced in the skin after exposure to the sun. Calcichew- D3 is used to treat and prevent vitamin D/calcium deficiency, which may occur when your diet or lifestyle does not provide enough, or when body requirements are increased. This medicine may also be prescribed or recommended for certain bone conditions, for example osteoporosis, or during pregnancy. 2.
BEFORE YOU TAKE CALCICHEW-D3
Do not take Calcichew-D3 Chewable Tablets if you:
• • • •
if you are on long term treatment, especially if you are taking medicines for a heart disorder (cardiac glycosides), or diuretics (used in the treatment of high blood pressure or oedema) if you have signs of impaired renal function or a high tendency to kidney stone (calculus) formation if you have cancer or any other conditions that may have affected your bones. if you have sarcoidosis (an immune system disorder which may cause increased levels of vitamin D in the body).
If you have any of the following conditions your serum calcium or phosphate levels, or urinary calcium excretion must be monitored. Calcichew should be taken under close medical supervision.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your pharmacist for advice before taking Calcichew-D3 . If you are pregnant, you may use Calcichew-D3 in case of a calcium and vitamin D deficiency. During pregnancy you should not take more than 2500 mg calcium and 4000 IU vitamin D per day, as overdoses may harm the unborn child. Calcichew-D3 can be used during breast-feeding. Calcium and vitamin D3 pass into breast milk. This should be considered when giving additional vitamin D to the child. Driving and using machines Calcichew-D3 has no known influence on the ability to drive or use machines. Calcichew-D3 contains isomalt and sucrose. Calcichew-D3 contains isomalt (E953) and sucrose (E420): if you have been told that you have an intolerance to some sugars, talk to your pharmacist before taking this medicine. May be harmful to teeth. 3.
e Calcichew- D3 3. How to take Calcichew-D3 4. Possible side effects 5. How to store Calcichew-D3 6. Contents of the pack and other information 1.
CALCICHEW-D3 CHEWABLE TABLETS
Always take Calcichew-D3 exactly as described in this leaflet or as your pharmacist has told you. Check with your pharmacist if you are not sure. Dosage The recommended dose is two or three tablets a day, preferably one tablet in the morning, one at midday and one in the evening. The tablet may be chewed or sucked. Children The recommended dose is two tablets a day, preferably one tablet in the morning and one tablet in the evening. The tablet may be chewed or sucked. If you take more than you should If you have taken more Calcichew-D3 than you should, talk to your pharmacist immediately. If you forget to take Calcichew-D3 Chewable Tablets Do not take a double dose to make up for a forgotten tablet. If you have any further questions on the use of this medicine, ask your pharmacist. 4.
POSSIBLE SIDE-EFFECTS
Like all medicines, this medicine can cause side effects, although not everybody gets them. Stop taking your medicine and see a doctor immediately if you experience:
Uncommon side effects (may affect up to 1 in 100 people):
with frequency not known (cannot be estimated from the available data):
CALCICHEW-D3 CHEWABLE TABLETS
Keep out of the sight and reach of children. Store in the original package. Keep the container tightly closed to protect from moisture. Do not store above 30°C. Do not use Calcichew-D3 after the expiry date which is stated on the label after EXP. The expiry date refers to the last day of that month. If the tablets have changed shape or colour do not use. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment. 6.
What Calcichew-D3 Chewable Tablets contain
The active ingredients in each tablet are:
If you are concerned about osteoporosis, please contact the National Osteoporosis Society, Camerton, Bath BA2 0PJ. Tel: 01761 471 771, Fax: 01761 471 104 or email: [email protected]. *Registered Trademark
Calcichew-D3 500 mg/200 IU Chewable Tablets comes as tablet containing 500mg / 200iu. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Calcichew-D3 500 mg/200 IU Chewable Tablets is calcium carbonate, colecalciferol; cholecalciferol.
This leaflet reproduces the patient information leaflet approved for Calcichew-D3 500 mg/200 IU Chewable Tablets, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Calcichew-D3 Chewable Tablets should be used only as a therapeutic and not as a food supplement when the diet is deficient or when normal requirement of both components is increased.
Calcichew-D3 Chewable Tablets may be used as an adjunct to specific therapy for osteoporosis or as a therapeutic supplement in established osteomalacia, pregnant patients at high risk of needing such a therapeutic supplementation or malnutrition when dietary intake is less than that required.
Posology
Adults
Adjunctive therapy in osteoporosis:
One tablet 2-3 times per day
Calcium and vitamin D deficiency:
One tablet 2-3 times per day.
Special Patient Populations
Elderly patients
Adjunctive therapy in osteoporosis
Calcium and vitamin D deficiency
Dosage as for adults.
Paediatric population
Calcium and vitamin D deficiency (only)
One tablet 1-2 times per day.
Impaired hepatic function
No dose adjustment is required.
Impaired renal function
Calcichew-D3 chewable tablets should not be used in patients with severe renal impairment (see section 4.3).
Method of Administration
Oral. The tablets should be chewed or sucked.
• Hypersensitivity to the active substances or to any of the excipients listed in section 6.1
• Severe renal impairment (glomerular filtration rate < 30 ml/min)
• Diseases and/or conditions resulting in hypercalcaemia and/or hypercalciuria
• Renal calculi (nephrolithiasis)
• Hypervitaminosis D
During long-term treatment, serum calcium levels should be followed and renal function should be monitored through measurement of serum creatinine. Monitoring is especially important in elderly patients on concomitant treatment with cardiac glycosides or diuretics (see section 4.5) and in patients with a high tendency to calculus formation. In case of hypercalcaemia or signs of impaired renal function, the dose should be reduced or the treatment discontinued.
Calcichew-D3 chewable tablets should be used with caution in patients with hypercalcaemia or signs of impaired renal function and the effect on calcium and phosphate levels should be monitored. The risk of soft tissue calcification should be taken into account. In patients with severe renal insufficiency, vitamin D in the form of colecalciferol is not metabolised normally and other forms of vitamin D should be used (see section 4.3, contraindications).
During concomitant treatment with other high dose sources of vitamin D and/or medications or nutrients (such as milk) containing calcium, there is a risk of hypercalcaemia and milk-alkali syndrome with subsequent kidney function impairment. In these patients serum calcium levels should be followed and renal function should be monitored.
Calcichew-D3 chewable tablets should be prescribed with caution to patients suffering from sarcoidosis because of the risk of increased metabolism of vitamin D to its active form. These patients should be monitored with regard to the calcium content in serum and urine.
Calcichew-D3 Chewable Tablets should be used with caution in immobilised patients with osteoporosis due to the increased risk of hypercalcaemia.
Calcichew-D3 Chewable Tablets contain isomalt (E953) and sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
Thiazide diuretics reduce the urinary excretion of calcium. Due to increased risk of hypercalcaemia, serum calcium should be regularly monitored during concomitant use of thiazide diuretics.
Calcium carbonate may interfere with the absorption of concomitantly administered tetracycline preparations. For this reason, tetracycline preparations should be administered at least two hours before, or four to six hours after, oral intake of calcium carbonate.
Hypercalcaemia may increase the toxicity of cardiac glycosides during treatment with calcium and vitamin D. Patients should be monitored with regard to electrocardiogram (ECG) and serum calcium levels.
If a bisphosphonate is used concomitantly, this preparation should be administered at least one hour before the intake of Calcichew-D3 Chewable Tablets since gastrointestinal absorption may be reduced.
The efficacy of levothyroxine can be reduced by the concurrent use of calcium, due to decreased levothyroxine absorption. Administration of calcium and levothyroxine should be separated by at least four hours.
The absorption of quinolone antibiotics may be impaired if administered concomitantly with calcium. Quinolone antibiotics should be taken two hours before or six hours after intake of calcium.
Calcium salts may decrease the absorption of iron, zinc and strontium ranelate. Consequently, iron, zinc or strontium ranelate preparations should be taken two hours before or after Calcichew-D3 Chewable Tablets.
Treatment with orlistat may potentially impair the absorption of fat-soluble vitamins (e.g. vitamin D3).
Pregnancy
Calcichew-D3 Chewable Tablets can be used during pregnancy, in case of a calcium and vitamin D deficiency. During pregnancy the daily intake should not exceed 2500 mg calcium and 4000 IU vitamin D. Studies in animals have shown reproductive toxicity with high doses of vitamin D (see section 5.3). In pregnant women, overdoses of calcium and vitamin D should be avoided as permanent hypercalcaemia has been related to adverse effects on the developing foetus. There are no indications that vitamin D at therapeutic doses is teratogenic in humans.
Lactation
Calcichew-D3 Chewable Tablets can be used during breast-feeding. Calcium and vitamin D3 pass into breast milk. This should be considered when giving additional vitamin D to the child.
Calcichew-D3 Chewable Tablets have no known influence on ability to drive and use machines.
Adverse reactions are listed below, by system organ class and frequency. Frequencies are defined as: uncommon (≥1/1,000, to <1/100); rare (≥1/10,000 to <1/1,000); very rare (≤1/10,000) or not known (cannot be estimated from the available data).
Immune system disorders
Not known: Hypersensitivity reactions such as angio-oedema or laryngeal oedema.
Metabolism and nutrition disorders
Uncommon: Hypercalcaemia and hypercalciuria.
Very rare: Milk-alkali syndrome (frequent urge to urinate; continuing headache; continuing loss of appetite; nausea or vomiting; unusual tiredness or weakness; hypercalcaemia, alkalosis and renal impairment). Seen usually only in overdose (see section 4.9).
Gastrointestinal disorders
Rare: Constipation, dyspepsia, flatulence, nausea, abdominal pain and diarrhoea.
Skin and subcutaneous disorders
Rare: Pruritus, rash and urticaria.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
Symptoms
Overdose can lead to hypercalcaemia and hypervitaminosis D. Symptoms of hypercalcaemia may include anorexia, thirst, nausea, vomiting, constipation, abdominal pain, muscle weakness, fatigue, mental disturbances, polydipsia, polyuria, bone pain, nephrocalcinosis, nephrolithiasis and in severe cases, cardiac arrhythmias. Extreme hypercalcaemia may result in coma and death. Persistently high calcium levels may lead to irreversible renal damage and soft tissue calcification. Milk-alkali syndrome may occur in patients who ingest large amounts of calcium and absorbable alkali.
Treatment of hypercalcaemia
Treatment is essentially symptomatic and supportive. The treatment with calcium and vitamin D must be discontinued. Treatment with thiazide diuretics and cardiac glycosides must also be discontinued (see section 4.5). Treatment is rehydration, and, according to severity of hypercalcaemia, isolated or combined treatment with loop diuretics, bisphosphonates, calcitonin and corticosteroids should be considered. Serum electrolytes, renal function and diuresis must be monitored. In severe cases, ECG and CVP should be followed.
Medicines sold in Romania with the same active substance: Cunoscut în România ca
⚠ Not the same combination. This medicine contains Calcium carbonate, Colecalciferol; cholecalciferol. The products below do not contain exactly the same set of active substances — they are not direct substitutes.
Some of these do not contain exactly the same active substances — check each one. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
Medicines sold in Poland with the same active substance: W Polsce znany jako
⚠ Not the same combination. This medicine contains Calcium carbonate, Colecalciferol; cholecalciferol. The products below do not contain exactly the same set of active substances — they are not direct substitutes.
Some of these do not contain exactly the same active substances — check each one. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Calcichew-D3 500 mg/200 IU Chewable Tablets. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.